Clinical Trial Update: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating A(B)VD chemotherapy followed by Nivolumab as frontline therapy for higher-risk classical Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Bleomycin (bleomycin)
• Dacarbazine (dacarbazine)
• Doxorubicin (doxorubicin)
• Vinblastine (vinblastine)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING